The future of cancer immunotherapy: your questions, answered

first_img Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED Log In | Learn More Biotech Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. @adamfeuerstein A CT scan of a lung cancer patient. Andy Wong/AP Last week, I hosted an hourlong webinar on future directions for cancer immunotherapy. I focused my talk on three promising avenues of research: checkpoint inhibitors that target the protein called TIGIT; cell therapies utilizing NK, or natural killer, cells; and messenger RNA-based cancer vaccines.The goal with all of these approaches is to increase the number of patients with cancer who can benefit from immunotherapy. By Adam Feuerstein March 29, 2021 Reprints Tags biotechnologycancerSTAT+center_img What is it? What’s included? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Adam Feuerstein GET STARTED [email protected] About the Author Reprints The future of cancer immunotherapy: your questions, answered last_img read more